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Objective: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP-
mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether
gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia.
Methods: Middle cerebral artery was occluded for 12 to 60 minutes in mice. We compared infarct risk and volumes,
collateral flow, and neurological deficits after pretreatment with olcegepant (single or 10 daily doses of 0.1–1mg/kg) or
rimegepant (single doses of 10–100mg/kg) versus vehicle. We also determined their potency on CGRP-induced relaxa-
tions in mouse and human vessels, in vitro.
Results: Olcegepant (1mg/kg, single dose) increased infarct risk after 12- to 20-minute occlusions mimicking transient
ischemic attacks (14/19 vs 6/18 with vehicle, relative risk = 2.21, p < 0.022), and doubled infarct volumes (p < 0.001)
and worsened neurological deficits (median score = 9 vs 5 with vehicle, p = 0.008) after 60-minute occlusion. Ten daily
doses of 0.1 to 1mg/kg olcegepant yielded similar results. Rimegepant 10mg/kg increased infarct volumes by 60%
after 20-minute ischemia (p = 0.03); 100mg/kg caused 75% mortality after 60-minute occlusion. In familial hemiplegic
migraine type 1 mice, olcegepant 1mg/kg increased infarct size after 30-minute occlusion (1.6-fold, p = 0.017). Both
gepants consistently diminished collateral flow and reduced reperfusion success. Olcegepant was 10-fold more potent
than rimegepant on CGRP-induced relaxations in mouse aorta.
Interpretation: Gepants worsened ischemic stroke in mice via collateral dysfunction. CGRP pathway blockers might
thus aggravate coincidental cerebral ischemic events. The cerebrovascular safety of these agents must therefore be
better delineated, especially in patients at increased risk of ischemic events or on prophylactic CGRP inhibition.
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Introduction
Migraine is a common paroxysmal neurovascular disorder,
typically characterized by disabling attacks of headache,
associated autonomic features, and in one-third of patients,
aura. Calcitonin gene–related peptide (CGRP) is an impor-
tant neurotransmitter within the migraine headache–
generating trigeminovascular system and believed to play a
crucial role in migraine pathophysiology.1 Gepants, short-
acting small molecule CGRP receptor antagonists, and
long-acting monoclonal antibodies targeting CGRP or the
CGRP receptor have recently emerged as promising acute
and prophylactic therapeutic options for migraine.2 Analysts
expect these drugs to be used by millions of migraineurs by
2027 in the G7 countries alone.3
CGRP is also among the most potent vasodilators in
animals and humans.4 It induces endothelium-independent
vasodilation via direct action on vascular smooth muscle
cells in cerebral and coronary vascular beds. Cerebral blood
flow (CBF) autoregulation is in part mediated by CGRP.5
Several lines of evidence suggest that CGRP-mediated vaso-
dilation is a rescue mechanism in brain ischemia.6 CGRP
released from trigeminal perivascular nerves7 is a potent
direct vascular smooth muscle dilator counteracting vaso-
constriction and hypoperfusion in the cerebrovascular
bed.5,8,9 Low pH- and ischemia-induced CGRP release
from perivascular C-fibers results in coronary and cerebro-
vascular vasodilation and restoration of circulation.10–12
Treatment with CGRP improves and genetic ablation of
CGRP worsens blood flow and outcomes after focal cere-
bral arterial occlusion in experimental animals.13–15 Admin-
istration of CGRP has shown beneficial effects in peripheral
and coronary artery disease16–18 and ameliorated experi-
mental cerebral and cardiac ischemia by preserving blood
flow and the blood–brain barrier.15,19–21 Consequently,
inhibition of the CGRP system with gepants or monoclonal
antibodies might theoretically worsen the outcome of coin-
cidental coronary and cerebral ischemic events.6
Despite these obvious concerns, remarkably few studies
have addressed the cardiovascular safety of inhibitors of
CGRP or its receptor. As far as we know, their cerebrovascu-
lar safety has never been studied. Patients with important
vascular risk factors were even excluded from most clinical
trials.22,23 This is all the more surprising because migraine
with aura is an established risk factor for ischemic stroke,
especially in women.24 The higher stroke risk is likely due to
increased risk of experiencing cerebral ischemic events25 in
combination with enhanced susceptibility of brain tissue to
infarction if and when such events occur.26,27 We, therefore,
investigated whether gepants worsen cerebral ischemic out-
comes, and the mechanism of this effect, in established
mouse models of transient ischemic attack (TIA) and stroke.
Materials and Methods
Experimental Animals and Design
Experiments were approved by the Massachusetts General Hos-
pital Institutional Animal Care and Use Committee and carried
out in accordance with the Guide for Care and Use of Labora-
tory Animals (NIH Publication No. 85-23, 1996). In addition
to wild-type mice (C57BL/6J), we also used heterozygous trans-
genic knock-in mice expressing the human familial hemiplegic
migraine type 1 (FHM1) S218L missense mutation in the α1A
subunit of CaV2.1 voltage-gated Ca
2+ channels and their wild-
type littermates.28 Mice were housed with their littermates, in
cages with standard embedding and enrichment, reversed light/
dark cycle, and food and water ad libitum. Whereas migraine is
most prevalent among women aged <50 years, the vast majority
of non–migraine-related strokes occur in the elderly, including
men. We, therefore, studied both young and aged mice (2–-
16 months), and both males and females. A priori sample size
determinations aimed to achieve 80% power to detect a 33%
effect size on infarct volume with 20% standard deviation of the
mean (α = 0.05, β = 0.20). Animals were randomized to treat-
ment arms using an online tool (CoinTosser, Hello Heydays and
Excel 2016, Microsoft, Redmond, WA). Each treatment group
had its own control group. Group sizes, exclusions, early mortal-
ity, and age and sex distributions for each experiment are shown
in Table S1. All investigators were blinded to the treatment
group during the surgical procedures, data collection, and
analysis.
Treatments
Animals were treated with the small molecule CGRP receptor
antagonists olcegepant (BIBN4096, 0.1 or 1mg/kg, 97.5%
purity, intravenous in acute and intraperitoneal in chronic treat-
ment; Tocris Bioscience, Bristol, UK) or rimegepant (BMS-
927711, 10 or 100mg/kg, intraperitoneal; 99.08% purity; Med-
ChemExpress, Monmouth Junction, NJ), either with a single
dose 10 minutes before ischemia onset (olcegepant and
rimegepant) or with 10 once-daily doses over 2 weeks followed
by a single dose 10 minutes before ischemia onset (olcegepant
only). These commercial vendors were selected based on previous
literature.29–31 Stock solutions were prepared in dimethyl sulfox-
ide and diluted as needed in saline (0.02–10mg/ml) to adminis-
ter the target dose in 4 to 10μl volume per gram of body weight.
Control groups received the same volume of identical vehicle via
the same route. The selected olcegepant doses were within the
previously reported dose range (1μg/kg–30mg/kg) in experimen-
tal models in rodents.29,30,32–37 In rats, 1mg/kg olcegepant,
which we used herein, has yielded a peak plasma concentration
of 0.8μM compared with peak plasma concentrations of approxi-
mately 0.15μM after a 10mg dose in clinical studies.34,38–41
Unfortunately, plasma concentrations of rimegepant have not
been reported in rodents or in humans. Rimegepant doses were
selected based on a single report in the marmoset,42 taking into
account (1) the significantly lower affinity of small molecule
CGRP receptor antagonists in rodents compared with
primates,43 as we confirmed herein using isolated vessels;
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(2) in vitro data showing significantly lower binding affinity for
rimegepant than olcegepant in isolated vessels31; and (3) the
7-fold higher efficacious human plasma concentrations of
rimegepant compared with olcegepant in clinical trials.38,44,45
Buprenorphine (0.08mg/kg, subcutaneous; Patterson Veterinary,
Devens, MA) was given as analgesic prior to surgery.
Focal Cerebral Ischemia
All experiments were carried out under isoflurane anesthesia (3%
induction, 1.5% maintenance in 70% N2O and 30% O2). Rec-
tal temperature was maintained at 36.7 ± 0.3C using a thermo-
static heating pad (FHC, Bowdoinham, ME). Focal ischemia
was induced using transient middle cerebral artery occlusion
(MCAO) by a nylon monofilament (701723Re, Doccol Corpo-
ration, Sharon, MA). After a ventral midline neck incision
(1–2cm), common carotid artery bifurcation was gently dissected
free of connected tissue, taking care to preserve the vagus nerve.
A closed system around the bifurcation was created, and the fila-
ment was inserted into the external carotid artery, retrogradely
guided into the internal carotid artery, and advanced until the
origin of the middle cerebral artery. After 12 to 60 minutes of
occlusion, the filament was removed to achieve reperfusion. CBF
was monitored (% of baseline) using laser Doppler flowmetry in
ischemic core (PeriFlux System 5000, Perimed, Järfälla-Stock-
holm, Sweden). In experiments with short occlusion times mim-
icking TIA in wild-type mice, and with 30-minute ischemia in
FHM1 mutant mice, CBF was recorded throughout the MCAO
and reperfusion. In 60-minute ischemia experiments, animals
were allowed to recover from anesthesia shortly after MCAO,
and reanesthetized for the reperfusion procedure; therefore, in
this cohort CBF monitoring was discontinued after MCAO.
After the surgical procedure, mice were placed in a temperature-
controlled heating chamber (32C) for 2 hours. At 24 hours
after MCAO, we quantified the sensorimotor deficits using a
scale ranging from 3 (normal) to 18 as previously described with
minor modifications.46 We then harvested the brain to measure
the infarct volume (mm3) by integrating the infarct area (ImageJ,
NIH, Bethesda, MD) on 1mm-thick coronal slices stained with
2,3,5-triphenyltetrazolium chloride, while correcting for ischemic
swelling using the following formula:
Infarct volume =
X10
n = 1
A nð Þ
B nð Þ=C nð Þð Þ 1mm
With A = direct infarct (mm2), B = total ipsilateral hemi-
sphere (mm2), C = total contralateral hemisphere (mm2), and
n = slice number. Exclusion criteria were incomplete MCAO
(residual CBF > 30% after anoxic depolarization) and subarach-
noid hemorrhage.
Resting CBF, Blood Pressure, and Heart Rate
A separate group of naive mice (male, C57BL/6J, 2–3 months
old) were anesthetized using 0.4ml of 20mg/ml Avertin in saline
solution (2,2,2-tribromoethanol, Sigma-Aldrich, St Louis, MO).
To examine resting CBF, laser Doppler flow probes were placed
bilaterally at 2mm posterior, 2mm lateral from the bregma. To
examine blood pressure and heart rate, a femoral artery catheter
was placed in an additional group of naive mice (male,
C57BL/6J, 2–3 months old). After 5 minutes of baseline record-
ings under isoflurane anesthesia (3% induction, 1.5% mainte-
nance in 70% N2O and 30% O2), vehicle or olcegepant
(1mg/kg) was administered via the tail vein, and measurements
continued for 30 minutes. All data were averaged in 5-minute
bins to plot the time course of changes.
Olcegepant and Rimegepant in Human and
Mouse Isolated Arteries
Mice (n = 11; 5 males, 6 females; 3–5 months of age) were
sacrificed at the Leiden University Medical Center in accordance
with the local committee for animal health, ethics, and research.
Aortas were isolated and immediately transported to the Erasmus
Medical Center, Rotterdam at 4C in Medium 199 (Lonza Bio-
science, Basel, Switzerland; transportation time  1 hour). Upon
arrival, aortas were stored in an oxygenated and carbonated
Krebs solution (118mM NaCl, 4.7mM KCl, 2.5mM CaCl2,
1.2mM MgSO4, 1.2mM KH2PO4, 25mM NaHCO3, and
8.3mM glucose, pH = 7.4) overnight. Human coronary arteries
were isolated from hearts of 7 heart valve donors (4 males and
3 females) aged 40 ± 5 years (mean ± standard error of the mean
[SEM]). The hearts were provided by ETB-BISLIFE, Multi Tis-
sue Bank (Beverwijk, the Netherlands), from Dutch post-mor-
tem donors, after donor mediation via the Dutch Transplant
Foundation (Leiden, the Netherlands), following removal of the
aortic and pulmonary valves for homograft valve transplantation.
All donors gave permission for research. Immediately after circu-
latory arrest, the hearts were generally stored at 4C in a sterile
organ-protecting solution and brought to the laboratory within
the first 24 hours after death. Distal portions of the left anterior
descending coronary artery were isolated and subsequently stored
in Krebs solution at 4C until the start of the experiment.
Human middle meningeal arteries were obtained from 4 individ-
uals (2 males, 2 females, aged 52 ± 9 years) undergoing neuro-
surgical procedures at the Erasmus Medical Center, Rotterdam,
the Netherlands. Middle meningeal arteries were stored in
Medium 199 and transported to the laboratory immediately.
Subsequently, surrounding tissue was removed and the artery
was stored in a cold oxygenated Krebs solution with a high glu-
cose content, as described before47 (119mM NaCl, 4.7mM KCl,
1.25mM CaCl2, 1.2mM MgSO4, 1.2mM KH2PO4, 25mM
NaHCO3, and 11.1mM glucose, pH = 7.4) at 4C overnight.
For functional experiments, human coronary arteries and mouse
aorta were cut into 2mm segments and mounted in Mulvany
myograph organ baths (Danish Myo Technology, Aarhus, Den-
mark), using Ø 40μm stainless-steel wires. Organ baths were
filled with oxygenated Krebs solution at 37C. Vessel segments
were allowed to equilibrate. Next, the segments were stretched to
a tension normalized to 0.9 times the estimated diameter at
100mmHg transmural pressure.48 Data were recorded using
LabChart data acquisition (AD Instruments, Oxford, UK). First,
all segments were exposed to 30mM KCl, followed by 100mM
KCl to determine the maximum contraction. Next, vessel
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segments were incubated with and without olcegepant (1μM,
3μM, or 10μM, dissolved in 1N HCl and diluted in distilled
water; Tocris Bioscience) or rimegepant (BMS-927711, 3μM,
10μM, or 30μM in mouse aorta, 1nM, 10nM, 100nM, or 1μM
in human coronary arteries, 1nM, 10nM, or 100nM in human
middle meningeal arteries, dissolved in dimethyl sulfoxide and
diluted in distilled water; MedChemExpress) for 30 minutes
before a concentration–response curve to human α-CGRP
(0.01nM–1μM, half logarithmic steps, human coronary artery
and human middle meningeal artery) or rat α-CGRP (0.01nM–
3μM, half logarithmic steps, mouse aorta) was constructed.
Precontraction was established using 30mM KCl, and the relaxa-
tion responses to CGRP were expressed as a percentage of
precontraction. Sigmoidal curves were constructed using non-lin-
ear regression. The pEC50 values were used to calculate dose
ratios for Schild plots. Using linear regression, the pA2 and/or
pKb values of the different antagonists in both human and
mouse tissue were determined.
Statistical Analysis
Primary outcome variables were infarct presence (TIA experi-
ment) or volume (stroke experiments). Secondary outcome vari-
ables were neurologic deficit score, CBF, heart rate, and blood
pressure. Neurological deficit scores were log-transformed to
achieve normality. Statistical tests were chosen based on the
experimental design. In the TIA experiments, we used multiple
logistic regression (independent variables: treatment, ischemia
duration; dependent variable: infarct presence) and Fisher exact
test (independent variable: treatment; dependent variable: infarct
presence). In stroke experiments using wild-type mice, we used
2-way analysis of variance (ANOVA; independent variables:
treatment, sex; dependent variables: infarct volume, neurological
deficits, CBF; interaction terms: treatment and sex when applica-
ble). In stroke experiments using FHM1 mice, we used multiple
linear regression (independent variables: treatment, age, sex;
dependent variable: infarct volume). For systemic physiology and
CBF, we used 2-way repeated measures ANOVA (independent
variables: time and treatment; dependent variables: blood pres-
sure, heart rate, and CBF). Grubbs’ method was used to identify
outliers. In isolated vessel experiments, we used 1-way ANOVA
for repeated measures (independent variable: CGRP concentra-
tions; dependent variable: relaxation) or mixed-effect model in
the case of missing values. All statistical tests, variables, sample
sizes, point estimates including 95% confidence intervals (CIs),
and exact 2-sided p values (prespecified α = 0.05) are provided
throughout the article where data are presented. Statistical tests
were carried out in Prism 8 (GraphPad Software, San Diego,
CA) and SPSS 20.0 (IBM, Armonk, NY).
Results
We first investigated whether CGRP receptor antagonism
increased the infarct risk after brief MCAO mimicking a
TIA. To this end, we treated mice (C57BL/6J, male,
2–3 months old) with a single dose of olcegepant (1mg/kg,
n = 19) or vehicle (n = 18) 10 minutes before brief MCAO
FIGURE 1: Olcegepant worsens the cerebral blood flow deficit
and outcome of 12-, 15-, or 20-minute focal cerebral ischemia.
(A) Experimental timeline. (B) 2,3,5-Triphenyltetrazolium
chloride–stained coronal brain sections showing the infarct
(blue arrows) after 12-minute middle cerebral artery occlusion
(MCAO) after pretreatment with a single dose of olcegepant
(1mg/kg), and normal brain 20-minute MCAO with vehicle
injection. (C) Stroke risk (%) in vehicle (Veh) and olcegepant
(Olce) groups after 12-, 15-, and 20-minute MCAO. Data
represent the percentage of infarct absence (transient ischemic
attack [TIA], gray portion) or presence (stroke, black portion).
Actual numbers of stroke/total are also provided in
parentheses under the bars. Data were analyzed using multiple
logistic regression (independent variables: treatment, ischemia
duration; dependent variable: infarct presence) for the entire
cohort, as well as using Fisher exact test in the 12-minute
MCAO group. (D) Representative cerebral blood flow tracing
during MCAO and reperfusion measured by laser Doppler
flowmetry. Gray shades represent typical time segments used
to quantify the CBF during ischemia and after reperfusion.
Lower panel shows the residual CBF (% of baseline) during
different stages of MCAO in vehicle (n = 18) and olcegepant
(1mg/kg, n = 19) arms (p = 0.029, 2-way repeated measures
analysis of variance). Data are from pooled 12-, 15-, and
20-minute MCAO experiments. Numbers within the gray bars
represent the relative difference between treatment arms
calculated as (CBFOlce/CBFVeh) − 1. AD = anoxic depolarization;
CCAO = common carotid artery occlusion; CCAR = common
carotid artery reperfusion; MCAR = middle cerebral artery
reperfusion. Seven mice in the vehicle arm and 1 mouse in the
olcegepant arm were excluded from analyses based on
predetermined criteria (see Materials and Methods). There was
no mortality.
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(12, 15, or 20 minutes; Fig 1). Manifest infarcts often
involved subcortical tissues (blue arrows). Multiple logistic
regression revealed significantly higher infarct risk associated
with olcegepant treatment (parameter estimate b = 2.44,
odds ratio [OR] = 11.4, 95% CI = 2.0–109.0, p = 0.013).
Three-quarters of all animals treated with olcegepant devel-
oped an infarct (14/19) compared with only 33% of
vehicle-treated animals (6/18) when all TIA durations were
pooled (relative risk = 2.21, 95% CI = 1.17–4.70,
p < 0.022, Fisher exact test). The increase in infarct risk by
olcegepant was most conspicuous with the shortest MCAO
time (12 minutes, p = 0.009, Fisher exact test). As
expected, infarct risk also showed a direct relationship to
ischemia duration (b = 0.48, OR = 1.6, 95% CI = 1.2–2.4,
p = 0.005). Given the known vasodilator role of CGRP in
cerebral vessels, we examined the CBF changes during
MCAO and found lower residual CBF (% of baseline) after
olcegepant treatment (1mg/kg, n = 19) compared with
vehicle (n = 18), which was apparent at every successive
stage of the occlusion procedure (p = 0.029; 2-way repeated
measures ANOVA).
After showing that olcegepant promotes transforma-
tion of brief ischemia (TIAs) into infarcts, we next tested
olcegepant in a more severe stroke model induced by lon-
ger occlusion time (Fig 2). Sixty-minute MCAO induced
infarcts in all mice, male and female, but these were >2-
fold larger (p < 0.001) and associated with more severe
neurological deficits (median deficit score = 9.0 vs 5.0,
p = 0.008) after a single dose of olcegepant (1mg/kg,
n = 9) compared with vehicle (n = 8, 2-way ANOVA,
independent variables: treatment and sex). Sex did not
affect the infarct volume (p = 0.509). Absence of an inter-
action between treatment and sex for infarct volume
(p = 0.579) and neurological deficits (p = 0.470) suggested
that olcegepant worsened outcomes in both sexes. The
lower residual CBF in the olcegepant arm did not reach
statistical significance in this experiment (p = 0.223, 2-
way ANOVA for repeated measures).
In the third series of experiments, we wanted to
assess whether the ischemia worsening effect is specific to
olcegepant or rather a class effect of CGRP receptor antag-
onists. We, therefore, studied rimegepant, a recently devel-
oped next generation small molecule CGRP antagonist.
First, we tested rimegepant (100mg/kg) in the 60-minute
MCAO model but encountered 75% (6/8) mortality com-
pared with none (0/8) in the vehicle group (p = 0.007,
Fisher exact test; Fig 3). The only 2 surviving mice in the
rimegepant group had infarct volumes of 85 and 109mm3
and neurological deficit scores of 13 and 16, compared
with a median infarct volume of 62mm3 and neurological
deficit score of 11 in the vehicle group. Once again, the
residual collateral CBF in rimegepant-treated animals was
lower than in the vehicle group (p = 0.014, 2-way
ANOVA for repeated measures). Because very high mor-
tality precluded the assessment of infarct volume, we next
FIGURE 2: Olcegepant worsens the outcomes after 60-minute
focal cerebral ischemia. (A) Experimental timeline.
(B) 2,3,5-Triphenyltetrazolium chloride–stained coronal brain
sections showing a typical infarct (unstained tissue) after
60-minute middle cerebral artery occlusion (MCAO). (C) Infarct
volume (mm3) and neurologic deficit score (p = 0.001 and
p = 0.011, respectively, 2-way analysis of variance [ANOVA]).
Data from individual animals are shown (triangles = male; circles
= female) along with their group median (red lines). Mean ages
were 5.3 ± 1.4 and 5.7 ± 1.5 months in the vehicle (Veh) and
olcegepant (Olce; 1mg/kg) groups, respectively (all wild type;
mean ± standard deviation). (D) Residual cerebral blood flow
(CBF; % of baseline) during MCAO (p = 0.223, 2-way repeated
measures ANOVA). Numbers within the gray bars represent the
relative difference between treatment arms calculated as
(CBFOlce/CBFVeh) − 1. Two mice in the vehicle arm and 1 mouse
in the olcegepant arm were excluded from analyses based on
predetermined criteria (see Materials and Methods). There was
no mortality.
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examined the effects of a 10-fold lower dose of rimegepant
(10mg/kg) versus vehicle in a 20-minute TIA model (Fig 4;
one outlier excluded from the rimegepant arm per Grubbs’
method). All animals survived and developed an infarct. In
rimegepant-treated mice, infarcts were approximately 60%
larger than in vehicle-treated mice (p = 0.030, unpaired
t-test), and residual CBF tended to be lower (p = 0.135, 2-
way ANOVA for repeated measures).
In the next series of experiments, we treated mice
with 10 once-daily doses of olcegepant (0.1 or 1mg/kg) or
vehicle over a 2-week period (Fig 5A), mimicking daily
dosing in migraine prophylaxis. Compared with vehicle,
both chronic dose levels increased the infarct volumes and
worsened the neurological deficit scores to a similar extent
as a single dose (see Fig 5B). These data suggested that,
within the 2-week timeframe tested, chronic CGRP block-
ade does not aggravate the adverse effect, or ameliorate it
by inducing alternative compensatory mechanisms restor-
ing collateral perfusion.
In a fifth set of experiments, we investigated whether
the ischemia-aggravating effect of CGRP-receptor antago-
nists might be even greater in FHM1 mice. These mice
have been shown to develop worse outcomes after cerebral
ischemia due to enhanced susceptibility to anoxic and
peri-infarct spreading depolarizations.26 To that end, we
tested the effects of a single dose of olcegepant (0.1 or
1mg/kg) versus vehicle 10 minutes before MCAO. To
avoid a ceiling effect for infarct volume and high mortal-
ity, we employed a 30-minute MCAO model (Fig 6A).
As the age range among the available FHM1 mice
bred in our facility was wider than for the wild-type mice
obtained from commercial vendors, we introduced age as
an independent variable in addition to sex and treatment
in a general linear model and determined the contribu-
tion of each independent variable to stroke outcome.
Whereas treatment (parameter estimate, β = 28.5, 95%
CI = 6.3–50.6, p = 0.014) and sex (β = 40.6, 95%
CI = 18.0–63.3, p = 0.001) significantly affected the
infarct volumes, age did not (β = −0.15, 95% CI =
−2.15 to 1.84, p = 0.875). In FHM1 mice, a single dose
of olcegepant (1mg/kg, n = 13) increased infarct volumes
by 75% compared with vehicle (n = 12, p = 0.017; see
Fig 6B). The effect of olcegepant, however, did not
appear to be stronger in mutant than in wild-type mice
(see Fig 2). As in wild-type mice, olcegepant (1mg/kg)
reduced collateral CBF in FHM1 mutants (p = 0.019, 2-
way ANOVA for repeated measures; see Fig 6). A sepa-
rate group treated with the lower dose of olcegepant
(0.1mg/kg) developed 50% larger infarcts compared with
vehicle, although this was not statistically significant
(p = 0.356). Tissue perfusion once again tended to be
worse (p = 0.052). Altogether, these data reproduced the
harmful effect of olcegepant on ischemic outcome but
did not support a higher sensitivity of FHM1 mutants to
CGRP blockade with olcegepant.
In a separate cohort, we sought to rule out systemic
hemodynamic changes as a potential explanation for the
effect of CGRP antagonism on collateral CBF. Because
accurate measurements of systemic blood pressure in mice
requires an indwelling arterial (often femoral) catheter, to
avoid excess morbidity we could not perform these experi-
ments in ischemic animals. Therefore, we studied
FIGURE 3: Rimegepant worsens the outcomes after 60-minute
focal cerebral ischemia. (A) Experimental timeline. (B) Infarct
volume (mm3) and neurologic deficit scores. Data from individual
animals are shown along with their group median (red lines).
Mean ages were 2.2 ± 0.2 and 2.3 ± 0.3 months in vehicle (Veh)
and rimegepant (Rime; 100mg/kg) groups, respectively (all male,
wild type; mean ± standard deviation). (C) Residual cerebral
blood flow (CBF; % of baseline) during middle cerebral artery
occlusion (MCAO; p = 0.014, 2-way repeated measures analysis
of variance). Numbers within the gray bars represent the relative
difference between treatment arms calculated as (CBFOlce/
CBFVeh) − 1. One mouse each in the vehicle and rimegepant
arms were excluded from analyses based on predetermined
criteria (see Materials and Methods). Six mice died prior to
outcome assessments in the rimegepant arm. AD = anoxic
depolarization; CCAO = common carotid artery occlusion. [Color
figure can be viewed at www.annalsofneurology.org]
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olcegepant (1mg/kg) in separate groups of naive non-
ischemic mice and found, consistent with previous
reports,37,49 no effect on systemic blood pressure, heart
rate, or resting CBF (Fig 7).
Finally, we sought to examine the relative potencies
of olcegepant and rimegepant in isolated mouse and
human blood vessels to confirm the dose ranges we
selected based on previous work (Fig 8).32–37,42,43 To this
FIGURE 5: Prolonged treatment with olcegepant worsens the outcomes after 60-minute focal cerebral ischemia. (A) Experimental
timeline. (B) Infarct volume (mm3) and neurologic deficit scores (p < 0.001 and p = 0.007, respectively, 2-way analysis of variance). Data
from individual animals are shown along with their group mean for infarct and median for neurologic score (red lines). All mice were
2 months old, male, and wild type. Two mice in the vehicle (Veh) and 3 mice in the olcegepant (Olce) 0.1mg/kg and olcegepant 1mg/kg
arms died prior to outcome assessments. There were no exclusions. [Color figure can be viewed at www.annalsofneurology.org]
FIGURE 4: Rimegepant worsens the outcomes after 20-minute focal cerebral ischemia. (A) Experimental timeline. (B) Infarct
volume (mm3; p = 0.030, t test). Data from individual animals are shown along with their group median (red lines). Mean ages
were 2.5 ± 0.3 and 2.4 ± 0.2 months in vehicle (Veh) and rimegepant (Rime; 10mg/kg) groups, respectively (all male, wild type;
mean ± standard deviation). (C) Residual cerebral blood flow (CBF; % of baseline) during middle cerebral artery occlusion
(MCAO; p = 0.135, 2-way repeated measures analysis of variance). Numbers within the gray bars represent the relative
difference between treatment arms calculated as (CBFOlce/CBFVeh) − 1. There was no mortality. AD = anoxic depolarization;
CCAO = common carotid artery occlusion; CCAR = common carotid artery reperfusion; MCAR = middle cerebral artery
reperfusion. [Color figure can be viewed at www.annalsofneurology.org]
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end, we tested these drugs. In mouse aorta, the 1μM,
3μM, and 10μM concentrations of olcegepant all signifi-
cantly shifted the concentration–response curve to rat α-
CGRP (control pEC50 = 8.02 ± 0.08, 1μM pEC50 =
6.55 ± 0.16, 3μM pEC50 = 6.35 ± 0.11, 10μM pEC50 =
5.41 ± 0.18, p < 0.001, mean ± SEM, 1-way ANOVA for
FIGURE 6: Stroke outcome in familial hemiplegic migraine type 1 (FHM1) mice after a single dose of olcegepant. (A) Experimental
timeline. (B) Infarct volume (mm3) and neurologic deficit scores in experiment testing olcegepant 1mg/kg (p = 0.017 and p = 0.374,
respectively, 2-way analysis of variance [ANOVA]). Data from individual animals are shown (triangles = male; circles = female) along
with their group median (red lines). Mean ages were 6.4 ± 4.5 and 7.0 ± 6.5 months in vehicle (Veh) and olcegepant (Olce) groups,
respectively (all FHM1 mutants; mean ± standard deviation [SD]). (C) Infarct volume (mm3) and neurologic deficit scores in
experiment testing olcegepant 0.1mg/kg (p = 0.356 and p = 0.440, respectively, 2-way ANOVA). Data from individual animals are
shown (triangles = male; circles = female) along with their group median (red lines). (D) Residual cerebral blood flow (CBF; % of
baseline) during middle cerebral artery occlusion (MCAO; p = 0.019, 2-way repeated measures ANOVA). Mean ages were
13.2 ± 3.9 and 12.3 ± 2.3 months in the vehicle and olcegepant (1mg/kg) groups, respectively (all FHM1 mutants; mean ± SD).
(E) Residual CBF (% of baseline) during MCAO (p = 0.052, 2-way repeated measures ANOVA). Numbers within the gray bars
represent the relative difference between treatment arms calculated as (CBFOlce/CBFVeh) − 1. Seven mice in the vehicle, 3 mice in
the olcegepant 0.1mg/kg, and 6 in the olcegepant 1mg/kg arms were excluded from analyses based on predetermined criteria
(see Materials and Methods). Two mice in the vehicle, 1 in olcegepant 0.1mg/kg, and 2 in the olcegepant 1mg/kg arms died prior
to outcome assessments. AD = anoxic depolarization; CCAO = common carotid artery occlusion; CCAR = common carotid artery
reperfusion; MCAR = middle cerebral artery reperfusion. [Color figure can be viewed at www.annalsofneurology.org]
778 Volume 88, No. 4
ANNALS of Neurology
repeated measures). The Schild plot slope of 1.16 (95%
CI = 0.65–1.66) did not differ significantly from unity. As
an estimate of the potency of olcegepant in mouse aorta,
the pA2 was 7.22 ± 0.20 (n = 4–5). Rimegepant concen-
trations of 3μM, 10μM, and 30μM shifted the
concentration–response curve to rat α-CGRP in mouse
aorta as well (control pEC50 = 8.21 ± 0.08, 3μM
pEC50 = 7.56 ± 0.11, 10μM pEC50 = 7.35 ± 0.22, 30μM
pEC50 = 6.96 ± 0.17, p < 0.001). The slope of the Schild
plot (0.71, 95% CI = 0.16–1.25) did not differ from
unity. The corresponding pA2 value for rimegepant in
mouse aorta was 6.24 ± 0.27 (n = 4). Similar experiments
were performed in human coronary arteries, in which
lower concentrations of rimegepant already significantly
shifted the concentration–response curve to human
α-CGRP (control pEC50 = 8.51 ± 0.08, 1nM pEC50 =
7.74 ± 0.11, 10nM pEC50 = 7.22 ± 0.14, 100nM
pEC50 = 6.77 ± 0.13, 1μM pEC50 = 6.08 ± 0.30,
p < 0.001). The Schild plot slope of 0.56 was significantly
smaller than unity (95% CI = 0.40–0.71); therefore, we
did not calculate a pA2 value. Instead, pKb values were
calculated for each individual concentration of rimegepant
to determine its potency in human coronary arteries
(1nM: 9.74 ± 0.05, 10nM: 9.25 ± 0.15, 100nM:
8.71 ± 0.16, 1μM: 8.43 ± 0.25). In human middle men-
ingeal arteries, all rimegepant concentrations visibly shifted
the concentration–response curve to CGRP, although only
the 10nM and 100nM concentrations reached statistical
significance (control pEC50 = 8.22 ± 0.15, 1nM
pEC50 = 7.63 ± 0.22, 10nM pEC50 = 6.62 ± 0.28,
100nM pEC50 = 5.71 ± 0.17, p = 0.002, n = 3–4). The
Schild plot slope of 0.91 did not differ from unity (95%
CI = 0.60–1.22), resulting in a pA2 value of 10.02 ± 0.33.
Discussion
CGRP receptor antagonists and antibodies targeting CGRP
or the CGRP receptor are highly publicized as novel, effec-
tive, and reportedly safe acute and prophylactic treatments
for migraine.3,22 CGRP-mediated collateral vasodilation,
however, is an important rescue mechanism in cerebral
ischemia, for which migraine is a risk factor. Here, we show
that single and chronic doses of 2 different gepants aggra-
vate experimental cerebral ischemia in standard mouse
models of cerebral ischemia. Both agents transformed TIA-
like mild ischemic events into full-blown infarcts and cau-
sed established infarcts to grow larger, with more severe
neurological deficits and higher mortality. These findings
call for a more careful assessment of the vascular safety of
CGRP inhibitors. This seems all the more pressing for
patients who are at increased risk of experiencing coincident
ischemic events, and patients who are using these agents
prophylactically, blocking CGRP pathways for prolonged
periods of time. Such patients are at increased risk of
experiencing ischemic events while their physiological pro-
tection system may be dysfunctional.
Thus far, no vascular safety issues have been
reported in clinical gepant and antibody trials,2,22
although a few cases with vascular events while on treat-
ment have appeared.22,50,51 Although this is reassuring, it
FIGURE 7: Baseline hemodynamic parameters in young male
wild-type mice after a single dose of olcegepant. Baseline
blood pressure (BP; p = 0.177), heart rate (HR; p = 0.917),
and cerebral blood flow (CBF; p = 0.441) were measured
over a period of 30 minutes after vehicle or olcegepant
(1mg/kg) treatment (both groups: 2.6 ± 0.2 months of age,
all male, wild-type mice). Two-way repeated measures
analysis of variance, n = 5 per group. BPM = beats per
minute.
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is important to note that the clinical trials to date were
not designed to detect the type of risk increase our data
suggest: not an increase in the risk of ischemic events, but
an increase in the risk of worse outcomes if and when
ischemic events happen while on treatment. The studies
were far too small and of too short a duration to detect
uncommon events such as stroke. Even more importantly,
patients with recent comorbid cardiovascular and cerebro-
vascular disease, who are at increased risk of experiencing
ischemic events, were excluded from participation in virtu-
ally all of these trials. Remarkably, despite serious theoreti-
cal and experimentally driven concerns,4,6 only a few
studies have specifically addressed the cardiovascular safety
of CGRP inhibitors, and only after single doses.52 None
of these studies, however, was conducted in the presence
of contemporaneous acute focal arterial occlusion. We are
also not aware of any study on the safety of long-term
inhibition for prophylactic purposes or specifically investi-
gating cerebrovascular safety. Single doses of CGRP inhib-
itors did not seem to exacerbate exercise-induced ischemic
symptoms and signs in patients with stable angina53,54
and appeared safe in a small cohort of migraine patients
with comorbid coronary artery disease.55 However, design
caveats diminished the predictive value of these studies for
cardiovascular safety.56 First, these studies were primarily
conducted in males, rather than females, which is surpris-
ing, because migraine has a 3:1 female preponderance and
the increased cardiovascular risk in migraineurs especially
affects women. Second, in the only study specifically
assessing the cardiovascular safety of a CGRP receptor
antibody,53,54 the cardiovascular system was challenged
and examined probably too soon after administration of
FIGURE 8: Pharmacological characterization of olcegepant and rimegepant in mouse aortas, human coronary arteries, and human
middle meningeal arteries. (A) Concentration–response curves to rat α–calcitonin gene–related peptide (CGRP) in mouse aortas
in the absence or presence of olcegepant (1μM, 3μM, and 10μM; 3–6 females and 3–5 males) with the corresponding Schild plot
(pA2 = 7.22, 2 females and 3 males). (B) Concentration–response curves to rat α-CGRP in mouse aortas in the absence or
presence of rimegepant (3μM, 10μM, 30μM; 2–5 females and 2–4 males) with the corresponding Schild plot (pA2 = 6.24, 3
females and 4 males). (C) Concentration–response curves to human α-CGRP in human coronary arteries in the absence or
presence of rimegepant (1nM, 10nM, 100nM, 1μM; 2–3 females and 3–4 males) with the corresponding Schild plot and pKb
values (3 females and 4 males). (D) Concentration–response curves to human α-CGRP in human middle meningeal arteries in the
absence or presence of rimegepant (1nM, 10nM, 100nM; 2 females and 1–2 males) with the corresponding Schild plot (pA2
= 10.02; 2 females and 2 males). All data are represented as mean ± standard error of the mean. DR-1 = Dose Ratio–1; KCL =
kaliumchloride; M = Molar
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the antibody, when vascular CGRP receptor blockade had
likely not yet been fully achieved.56 A potentially harmful
effect of CGRP receptor blockade could have been missed.
Remarkably, despite this conspicuous lack of formal safety
data, comorbid vascular disease has not been listed as a
formal contraindication for CGRP pathway inhibitors.
To inhibit CGRP-mediated collateral vasodilation
in vivo after systemic administration, CGRP receptor
blockers must gain access from the blood vessel lumen
across the endothelium to the CGRP receptors on the
smooth muscle layer. There is major debate whether, and to
what extent, gepants and monoclonal antibodies cross the
blood–brain barrier under physiological conditions.45,57–59
Our data show that, in mice, systemic administration of
gepants impairs the ability of the cerebral vasculature to
redirect collateral CBF to ischemic brain tissue upon focal
arterial occlusion. Thus, under ischemic conditions, small
molecule CGRP receptor antagonists may cross the endo-
thelial blood vessel wall to reach cerebrovascular CGRP
receptors in concentrations sufficient to prevent pial vasodi-
lation normally resulting from ischemia-induced local release
of endogenous CGRP. Whether this also applies to human
cerebral vasculature and to anti-CGRP or CGRP receptor
antibodies remains to be investigated. Currently available
antibodies, however, are human (erenumab) or humanized
(eptinezumab, fremanezumab, galcanezumab) and, except
for galcanezumab,60 either do not bind or have not been
tested against rodent targets, hampering studies in experi-
mental animals. Although species differences must always
be considered when interpreting experimental work, to
date there are no data to suggest functionally important
differences in the CGRP system and ischemia-
compensating mechanisms between rodent and human
cerebral vasculature.
Taken together, our data indicate that the doses
employed in the current study are relevant, because the
10-fold difference in dosing for olcegepant (1mg/kg) and
rimegepant (10mg/kg) matched their relative potencies in
blocking α-CGRP–induced relaxation of isolated mouse
aortas. For both antagonists, the slope of the Schild plot
did not differ from unity, suggesting a competitive type of
antagonism in mouse aorta. However, the shift of the
concentration–response curve by increasing concentrations
of olcegepant to some extent appeared to be biphasic, sim-
ilar to what was observed for olcegepant in human coro-
nary arteries.61 A second CGRP receptor, such as the
amylin type 1 receptor, may be responsible for the poten-
tially biphasic effect as observed in the Schild plot.62 Both
olcegepant and rimegepant were less potent in mouse
aorta than in human coronary artery. The shift in the
concentration–response curve to α-CGRP induced by
rimegepant appeared to decrease for increasing
concentrations of the antagonist, which is again suggestive
of involvement of multiple receptors. Therefore, the pKb
of the lowest concentration of rimegepant (1nM) that
induced a shift in the concentration–response curve to
α-CGRP was used as a measure of potency, as it likely
represents the potency at the canonical CGRP receptor.
The pKb at 1nM rimegepant in human coronary artery and
the pA2 in mouse aorta together suggested 3,000-fold
higher potency in human coronary arteries compared with
mouse aorta. Rimegepant was even more potent in human
middle meningeal arteries compared with human coronary
arteries (2-fold). Olcegepant was also more potent in
human coronary arteries compared to mouse aorta (200-
fold) based on the previously published pKb of 9.56 ± 0.22
for 1nM olcegepant.61 Olcegepant was shown to be slightly
more potent in human middle meningeal artery as well
(10-fold, pA2 = 10.59 ± 0.54).
63 Although the potency of
CGRP receptor antagonists may vary across different vascu-
lar beds, as shown here and in our previous work with
telcagepant,64,65 the interspecies differences are much
larger.
Residual blood flow within ischemic core is criti-
cally dependent on pial collaterals, the magnitude of
which determines how long the tissue survives during the
ischemic event before irreversible injury and infarction.
The absolute differences in residual CBF between gepant
and vehicle groups in ischemic core, where residual CBF
was already <20% of baseline in most animals, were
small but important, and likely reflected poor collateral
function and larger perfusion defects after treatment with
gepants. Interestingly, reduced CBF in the gepant arms
always got worse after anoxic depolarization, suggesting
that endogenous CGRP opposes the vasoconstrictive
coupling during anoxic depolarization, consistent with
CGRP-mediated vasodilation during spreading depolar-
izations.66 Last but not the least, recanalization was also
less effective in restoring CBF in gepant arms, suggesting
that CGRP antagonism worsens the no-reflow phenome-
non. These findings indicate that CGRP antagonism
abrogates an important endogenous defense mechanism
to counteract low perfusion pressure and high vascular
tone that develops in the ischemic brain, and thereby
renders the brain more susceptible to infarction upon
arterial occlusions.
Hypothetically, long-term blockade of CGRP path-
ways could lead to upregulation of alternative rescue
mechanisms in cerebral ischemia. For the brain, we did
not find any indication that alternative mechanisms take
over the anti-ischemic effects of CGRP-mediated collat-
eral vasodilation. After 2 weeks of daily treatment with
olcegepant, infarcts and neurological deficits remained
negatively affected by gepants. This is well in line with
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worse stroke outcomes reported in CGRP knockout
mice.14
Lastly, we advise caution when extrapolating our
experimental data to the clinical setting. Clearly, the
murine dose ranges, pharmacokinetics, formulations, and
delivery routes of olcegepant and rimegepant used in our
study were different from those in humans. Guided by
previously published studies,29–31 we obtained the drugs
from commercial vendors (Tocris Bioscience, Med-
ChemExpress), rather than the pharmaceutical companies
that developed the clinical preparations, and relied upon
the product data sheets and purity reports provided by
these vendors, all of which are publicly available. Although
we have picked the dose ranges from the existing
literature,29–38,42–45 as a caveat we have not measured the
plasma or brain drug levels to inform us about the rele-
vance of the dose–route combination used in our study to
clinical dose–route combinations. However, as both antag-
onists we tested showed much higher potency in human
compared with mouse vessels, lower plasma levels may be
sufficient to observe the same effect on stroke outcomes in
humans. Lastly, the widely used middle cerebral artery
occlusion procedure by an intraluminal filament might
have facilitated drug access into the brain. Future studies
using other models are needed to eliminate this potential
caveat.
In summary, CGRP receptor antagonists and, by
inference, likely also CGRP or CGRP receptor antibodies
may worsen the outcome of coincidental cerebral ischemic
events by blocking CGRP-mediated vascular rescue mech-
anisms. Many migraineurs are soon expected to be using
these agents. Therefore, their cerebrovascular safety must
be urgently defined in migraineurs with comorbid vascular
disease who are at risk of experiencing ischemic events,
and in prophylactic CGRP inhibition where long-term
exposure occurs.
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